Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2024, titled "Sentynl Therapeutics receives marketing authorization for NULIBRY?? (fosdenopterin) from the UK MHRA for treatment of MoCD Type A".
Press Release Apr 20 2024
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited announced that its subsidiary Sentynl Therapeutics has received marketing authorization from the UK MHRA for NULIBRY, the first treatment for Molybdenum Cofactor Deficiency Type A. This approval allows access to a critical therapy for an ultra-rare genetic disorder that primarily affects infants. NULIBRY is already approved in the US and has received Orphan Drug status in the UK. The press release emphasizes the significance of this development for patients suffering from this life-threatening condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 01 2024
- Press Release Mar 23 2024
- Press Release Mar 16 2024
- Press Release Mar 14 2024
- Press Release Mar 13 2024
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Apr 22 2024
- Press Release Apr 23 2024
- Press Release Apr 26 2024
- Press Release May 04 2024
- Press Release May 09 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences